Editorial

Lyme Borreliosis

In the last few years, we observed many developments about Lyme disease, especially in microbiological, clinical and therapeutical research fields.

We better understood the mechanisms through which Borrelia protects itself from human immune system and new species of Borrelia related to Lyme disease have been identified [1 - 10].

Focusing on clinical aspects, new correlations between Lyme and other diseases have been reported, such as Cutaneous Marginal Zone B-cell Lymphomas, recalling Mucosa Associated Lymphoid Tissue Lymphoma caused by Helicobacter pylori [11 - 14]. Atrophosclerodermic diseases related to Lyme disease, such as morphea, lichen sclerosus et atrophicus and Parry-Romberg hemiatrophy, still remain debated [15 - 29]. Neuroborelliosis is still a frequent challenging manifestation both for diagnosis and for treatment [30 - 33].

In some areas of the world, like in Brazil and the Amazon rainforest, Lyme disease can show a peculiar feature associated with autoimmune reactions, perhaps due to the transmission of Borrelia by Amblyomma sp. Instead of Ixodes complex ticks (Baggio-Yoshinari Syndrome) [34].

In the therapeutic management it is important also to document the possible co-infection by Ehrlichia (Anaplasma phagocytophilum in Europe), Rickettsia spp, Bartonella spp and Babesia (microti in USA, divergens and venatorum in Europe), especially when the clinical manifestations are atypical [35, 36]. Lyme disease, in some cases, combines infectious, immunological and proliferative aspects, becoming an entity difficult to recognize, treat and manage. Treatment of Lyme disease follows the traditional guidelines for early and late Borreliosis, while in the resistant forms the use of some other drugs such as metronidazole or hydroxychloroquine is on discussion [37, 38].

Fortunately Borrelia infection is mostly recognized early (erythema migrans) and antibiotic treatment with amoxicilline or doxycycline almost always leads to heal but complicated cases are often diagnosed too late.

ORGANIZATION OF THE VOLUME

At the beginning of this special issue we report the contributions that deal with Borrelia genotyping (Eva Ružić-Sabljić) and the epidemiology of Lyme disease in domestic and wild animals (Vittorio Sala). After providing an update on microbiology we analyze clinical aspects focusing on atrophosclerodermic manifestations (Elisabeth Aberer) and nervous system involvement in Lyme borreliosis (Vera Maraspin). We report the impact of co-infections (Giuseppe Stinco) and a review of diagnostic tools for Borrelia assessment in humans (Serena Bonin) before concluding with the issue of therapy (Giusto Trevisan).

In the first article Eva Ružić-Sabljić and Cerar Tjaša describe Borrelia genotyping. Borrelia burgdorferi sensu lato is the causative agent of Lyme borreliosis while different borrelia species can lead to distinct clinical presentations and some species are associated with defined clinical manifestation like Borrelia afzelii with skin manifestations, Borrelia garinii with central nervous system disorders and Borrelia burgdorferi sensu stricto with Lyme arthritis. Genotyping of Borrelia strains is of great importance for epidemiological, clinical, and evolutionary studies. The authors review the different typing methods that recently have been implemented more or less successfully for diagnostic purposes.

In the second contribution Vittorio Sala and Eleonora De Faveri review the main aspects of Lyme Borreliosis epidemiology in animals (domestic and wild) and ticks. In particular, the environmental interference on the interactions between different hosts, including humans as terminal host are focused. The authors analyze the species of ticks and the
prevalence of *Borrelia* species in the diverse continents. The function of the reservoirs animal is also different and depends on the belonging species. As the climatic variations and the changes in the duration of seasons interfere with the biological cycles of the animal species, arthropods and bacteria, a gradual change occurs in the epidemiology of the infection and of the clinical evidence of the disease in different animal species and humans. Finally, the implications of Lyme disease in the field of social health have been considered.

Focusing on clinical aspects, in the third article, Elisabeth Aberer and Nora Wutte summarize the literature on scleratrophic skin lesions as a manifestation of a *Borrelia* infection. An association of morphea, acrodermatitis chronica atrophicans, lichen sclerosus et atrophicus and anetoderma have been observed. Since all these diseases show clinical and histological similarities, it has been hypothesised that they might have a common origin. The laboratory results that point to a borrelial origin of these diseases, however, are contradictory. The response of scleratrophic skin lesions to antibiotic treatment varies and can be seen in patients with or without a proven association to a *Borrelia* infection. This suggests that scleratrophic diseases might be of heterogeneous origin, but a *Borrelia* infection could be one cause of these dermatoses.

As second contribution on clinical update, Vera Maraspin and Katarina Ogrinc review neurological manifestations in Lyme disease. Lyme neuroborreliosis is the second most frequent manifestation of Lyme borreliosis in Europe, while it comprises the third most common expression of the disease in North America. The authors review the different feature of early Lyme neuroborreliosis, in Europe (with the classical triad of meningitis, radiculoneuritis, cranial neuropathy) and in America (with subacute meningitis with or without cranial neuropathy), and the chronic forms (peripheral neuritis with acrodermatitis chronica atrophicans). In this article, the challenging diagnosis and antibiotic treatment of neuroborreliosis are analyzed.

In the fifth contribution, Giuseppe Stinco and Serena Bergamo analyze the impact of co-infections in Lyme disease. In the recent years co-infections emerged as an important issue in Lyme disease spectrum. In this review the association of *Borrelia* infection and *Anaplasma phagocytophilum, Babesia spp, Bartonella spp, Rickettsiae spp* and tick-borne encephalitis virus is reported. For each single co-infecting micro-organism, clinical features, diagnostic issues and therapeutical approaches are discussed. They might exacerbate Lyme disease clinical features, they can also mimic Lyme borreliosis sharing common manifestations, and eventually they can change the course of the disease itself. The presence of one or more co-infecting agent during the course of Lyme disease may represent an issue especially in endemic areas for tick-borne diseases and in people occupationally exposed.

The sixth chapter is dedicated to diagnostic tools in assessment of Lyme disease described by Serena Bonin. Although the etiological agent has been known since 1980s, diagnosis of Lyme disease is still a controversial topic because of the wide range of clinical manifestations and the limited diagnostic tools available to assess *Borrelia* in humans. The most used diagnostic tool for Lyme disease is currently serology, but also Polymerase chain reaction (PCR) and other methods are often used to prove *Borrelia* infection in different patients’ specimens. The present article deals with most of the diagnostic tools used in clinical practice for Lyme disease detection in human samples. Direct and indirect specific methods for *Borrelia* infection detection is discussed. The author analyse the most recent peer reviewed publications as well as original results and information provided by companies’ web sites.

After etiological, epidemiological, clinical and diagnostic issues, the last article is dedicated to the therapy of Lyme disease reviewed by Giusto Trevisan. *Borrelia burgdorferi* is highly susceptible to antibiotic treatment and the majority of patients profit from this treatment. Antibiotic selection, dose and route of administration, and duration of therapy for Lyme disease depend on the patient’s clinical manifestations and stage of disease, age, pregnancy status, as well as the presence of other concomitant diseases and/or allergies. Despite an appropriate antibiotic therapy, about 10-20% of patients may show persistent or recurrent symptoms ("post-treatment Lyme disease syndrome").

The author discusses on the post-exposure prophylaxis, the current therapeutic approach, the main treatment-related phenomenon, the Jarisch-Herxheimer reaction, and the treatment modalities for special categories of patients.

In sum, we hope that the present paper presented in this special issue constitute a useful reference for researchers as well as for daily practice in the domain of Lyme disease.

**CONFLICT OF INTEREST**

The authors confirm that this article content has no conflict of interest.
ACKNOWLEDGEMENTS

We thank the reviewers, Alexander Kreuter, Snezana Tomanovic, Octavija Rode, Walter Berghoff, Anna Moniuszko, Tjasa Cerar, Klaus Einsendle, for their comments and commendable contributions to this special issue.

REFERENCES


Giusto Trevisan
Department of Dermatology and Venereology
University of Trieste
Trieste
Italy
Email: ltrevisan@units.it
Sara Trevisini  
Department of Dermatology and Venereology  
University of Trieste  
Trieste  
Italy  

Nicola di Meo  
Department of Dermatology and Venereology  
University of Trieste  
Trieste  
Italy  

© Trevisan et al.; Licensee Bentham Open.  
This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.